Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
A minimal tripeptide (Pro-Leu-Gly-NH₂) from the hypothalamus: the fragment the body uses to brake MSH release. It has been studied in pilot work on mood and movement disorders.
Size: 10 mg
No published analyses yet.
Research, properties and limitations
AI can make mistakes
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Period / condition | Dose | Escalation |
|---|---|---|
| Base cycle (day 1–5) | 10 mg subcutaneously, once daily, 5 consecutive days | Starting dose |
| Repeat cycle | 10 mg/day × 5 days after a 2-day to 1–2-week washout | , |
| Higher doses | 75 mg/day orally in some reports gave a weaker effect than the low dose | Maximum in this schedule (inverted-U curve) |
Research overview · reference
Below is a short summary of what the authors of published studies reported. It is not medical advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Adverse events | 20 patients with major depression, subcutaneous MIF-1 | The abstract describes subcutaneous administration but gives no adverse-event frequencies | [1] |
| Reduced morphine analgesia (interaction signal) | Eight men, crossover study: an MIF-1 capsule before morphine | Experimental analgesia decreased; an interaction signal, not a complication frequency | [2] |
FAQ
Find answers to questions about MIF-1 (Pro-Leu-Gly-NH₂) and related materials.
MIF-1 (Pro-Leu-Gly-NH₂, also called PLG) is a tripeptide first described as a hypothalamic factor that brakes the release of melanocyte-stimulating hormone (MSH). The molecule is minimal — three amino acids — but it carries a long research history: it is looked at in relation to the dopamine system, mood and movement disorders.
Source / documentationMostly in relation to the dopamine system: pilot work has looked at it for mood and movement disorders. The data is pilot-scale and scarce. Details are in the MIF-1 monograph in our wiki.
Source / documentationAn interesting feature from the pilot protocols: MIF-1 dosing is not linear. Short cycles of 10 mg under the skin daily produced a different effect profile than much higher oral doses, which in some studies turned out weaker than the lower dose. So "more" does not mean "stronger" here — worth understanding before working with the protocols.
Source / documentationIn pilot protocols — under the skin in short cycles (see the previous question about non-linearity). There is no established regimen. Reference points are in the dosing guide on this page.
Source / documentationThere is no systematic safety data: the data is pilot-scale and scarce, so an honest list of side effects cannot be compiled. A full review of the known data is in the MIF-1 monograph in our wiki.
Source / documentationKeep the dry powder in a dry, dark place at a low temperature; once dissolved, store it in the refrigerator and do not freeze it again. Details are in the MIF-1 guide on this page.
Source / documentationYou can buy MIF-1 right on this page of our store: current prices and stock are shown in the product card. We deliver across Ukraine with Nova Poshta — to a branch, a parcel locker, or by courier. Payment is by card, by crypto (with a 5% discount), or on delivery. Every vial ships with the certificate of analysis (COA) for its exact batch.
Source / documentationShare your experience
No reviews yet. Tell others what you think of this product.
MIF-1 (Pro-Leu-Gly-NH₂, also called PLG) is a tripeptide first described as a hypothalamic factor that brakes the release of melanocyte-stimulating hormone (MSH). The molecule is minimal — three amino acids — but it carries a long research history: it is looked at in relation to the dopamine system, mood and movement disorders.
An interesting feature from the pilot protocols: MIF-1 dosing is not linear. Short cycles of 10 mg under the skin daily produced a different effect profile than much higher oral doses, which in some studies turned out weaker than the lower dose. So "more" does not mean "stronger" here — worth understanding before working with the protocols.
Honestly about the limits: the data is pilot-scale and scarce, with no established regimen. Reference points are in the dosing guide; the full line is in the melanocortin category, and the system's older relative is melanotan II.
Every batch is purity-tested by HPLC, and the certificate of analysis (COA) for your exact batch is in our COA archive. Keep the dry powder in a dry, dark place at a low temperature, and the dissolved solution in the refrigerator.